Envestnet Portfolio Solutions Inc. Sells 1,510 Shares of DexCom, Inc. $DXCM

Envestnet Portfolio Solutions Inc. lessened its holdings in DexCom, Inc. (NASDAQ:DXCM) by 12.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 11,055 shares of the medical device company’s stock after selling 1,510 shares during the quarter. Envestnet Portfolio Solutions Inc.’s holdings in DexCom were worth $965,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Golden State Wealth Management LLC increased its holdings in DexCom by 211.2% in the 1st quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company’s stock valued at $27,000 after buying an additional 264 shares during the period. Zions Bancorporation National Association UT bought a new stake in DexCom in the 1st quarter valued at $27,000. Anderson Financial Strategies LLC bought a new stake in DexCom in the 1st quarter valued at $37,000. Alpine Bank Wealth Management bought a new stake in DexCom in the 1st quarter valued at $40,000. Finally, Private Trust Co. NA increased its holdings in DexCom by 99.4% in the 1st quarter. Private Trust Co. NA now owns 672 shares of the medical device company’s stock valued at $46,000 after buying an additional 335 shares during the period. Institutional investors own 97.75% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on DXCM shares. Wall Street Zen downgraded shares of DexCom from a “strong-buy” rating to a “buy” rating in a research note on Sunday, August 10th. Morgan Stanley boosted their target price on shares of DexCom from $82.00 to $89.00 and gave the company an “equal weight” rating in a research note on Tuesday, July 15th. Robert W. Baird reduced their target price on shares of DexCom from $112.00 to $90.00 and set an “outperform” rating on the stock in a research note on Friday, September 26th. Piper Sandler boosted their target price on shares of DexCom from $90.00 to $100.00 and gave the company an “overweight” rating in a research note on Thursday, July 31st. Finally, Truist Financial reduced their target price on shares of DexCom from $102.00 to $94.00 and set a “buy” rating on the stock in a research note on Wednesday. Three analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $97.00.

Insider Activity at DexCom

In related news, Director Kyle Malady sold 667 shares of the company’s stock in a transaction dated Friday, September 5th. The shares were sold at an average price of $80.86, for a total transaction of $53,933.62. Following the transaction, the director owned 22,667 shares in the company, valued at $1,832,853.62. This represents a 2.86% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Michael Jon Brown sold 500 shares of the business’s stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $80.29, for a total value of $40,145.00. Following the sale, the executive vice president directly owned 94,102 shares of the company’s stock, valued at $7,555,449.58. This represents a 0.53% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 6,849 shares of company stock worth $564,733 in the last 90 days. Corporate insiders own 0.32% of the company’s stock.

DexCom Stock Up 0.4%

Shares of NASDAQ DXCM opened at $66.60 on Friday. The firm’s 50-day simple moving average is $73.35 and its 200 day simple moving average is $77.58. The company has a market cap of $26.12 billion, a price-to-earnings ratio of 46.25, a price-to-earnings-growth ratio of 1.40 and a beta of 1.47. The company has a quick ratio of 1.35, a current ratio of 1.52 and a debt-to-equity ratio of 0.48. DexCom, Inc. has a 12-month low of $57.52 and a 12-month high of $93.25.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Wednesday, July 30th. The medical device company reported $0.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.45 by $0.03. The business had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The firm’s quarterly revenue was up 15.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.43 EPS. DexCom has set its FY 2025 guidance at EPS. On average, research analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.